Patents by Inventor HAILONG JIANG

HAILONG JIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVE TNFR1 ANTAGONIST PEPTIDE SN10 AND APPLICATION THEREOF IN INFLAMMATORY BOWEL DISEASE
    Publication number: 20200277355
    Abstract: The invention relates to the field of biomedicine, and in particular to a selective TNFR1 antagonist peptide Hydrostatin-SN10 derived from the snake venom of the ringworm, having the amino acid sequence as shown in SEQ ID NO: 2. The invention also provides a selective TNFR1 antagonist peptide PEG-SN10 based on mPEG2000 modification, which is modified by covalent attachment of the carboxyl group of mPEG2000 to the free amino group of the N-terminal aspartic acid of the Hydrostatin-SN10 peptide chain. At the same time, the present invention provides Hydrostatin-SN10 and PEG-SN10 for the treatment of inflammatory bowel disease.
    Type: Application
    Filed: March 2, 2018
    Publication date: September 3, 2020
    Inventors: Yiming LU, HAILONG JIANG, YINGYING BIAN, JIE WANG, AN LI, CHUAN ZHANG
  • APPLICATION OF SELECTIVE TNFR1 ANTAGONIST PEPTIDE SN10 IN PREPARATION OF DRUGS FOR PREVENTING AND TREATING RHEUMATOID ARTHRITIS
    Publication number: 20200188471
    Abstract: The invention relates to the field of biomedicine, in particular to providing a selective TNFR1 antagonist peptide derived from the snake venom of Qinghai Hydrostatin-SN10 has the amino acid sequence as shown in SEQ ID NO: 2. The present invention also provides a selective TNFR1 antagonist peptide PEG-SN10 based on mPEG2000 modification, which is selectively modified by covalent attachment of the carboxyl group of mPEG2000 to the free amino group of the N-terminal aspartic acid of Hydrostatin-SN10 peptide chain. At the same time, the present invention provides the use of the selective TNFR1 antagonist peptides Hydrostatin-SN10 and PEG-SN10 for the prevention and treatment of rheumatoid arthritis.
    Type: Application
    Filed: March 2, 2018
    Publication date: June 18, 2020
    Applicant: GUILIN EIGHT PLUS ONE PHARMACEUTICAL CO., LTD.
    Inventors: YIMING LU, JIE WANG, AN LI, HAILONG JIANG, YINGYING BIAN, CHUAN ZHANG
  • Inkjet pen
    Patent number: D894265
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: August 25, 2020
    Assignee: Shenzhen Eve-Innovations Technology Co., Ltd.
    Inventors: Hailong Jiang, Xiang Li